Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study

Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study


Adaptimmune Therapeutics plc , a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY-ESO SPEARa T-cells in myxoid/round cell liposarcoma . Patient screening is underway, and the results from this study in up to 15 patients will inform a potential future registration trial.



from Biotech News